Correction: Osimertinib in combination with anti-angiogenesis therapy presents a promising option for osimertinib-resistant non-small cell lung cancer

• Ruoshuang Han,
• Haoyue Guo,
• Jinpeng Shi,
• Sha Zhao,
• Yijun Jia,
• Xiaozhen Liu,
• Yiwei Liu,
• Lei Cheng,
• Chao Zhao,
• Xuefei Li,
• Caicun Zhou

Affiliations

Ruoshuang Han

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine

Haoyue Guo

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine

Jinpeng Shi

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine

Sha Zhao

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine

Yijun Jia

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine

Xiaozhen Liu

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine

Yiwei Liu

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine

Lei Cheng

Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine

Chao Zhao

Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine

Xuefei Li

Department of Lung Cancer and Immunology, Shanghai Pulmonary Hospital, Tongji University School of Medicine

Caicun Zhou

Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University School of Medicine